share_log
Reuters ·  05/01 06:33

Kalvista Pharmaceuticals: Intend to Reduce Spending on Discovery & Preclinical Activities by More Than 75%, to Less Than $5 Mln per Year

Kalvista Pharmicals:打算将研发和临床前活动的支出减少75%以上,至每年不到500万美元

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发